Glycyrrhizin, ammoniated

Drug Profile

Glycyrrhizin, ammoniated

Alternative Names: Glycyron Tablets; Stronger Neo-Minophagen C

Latest Information Update: 20 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Minophagen
  • Developer Erasmus Medical Center; Minophagen; University of Texas System
  • Class Antiulcers; Antivirals; Triterpenes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C
  • Discontinued Influenza virus infections

Most Recent Events

  • 18 Dec 2007 Eisai enters into in-licensing agreement with Minophagen for Japan and other countries
  • 14 Nov 2007 Data presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2007) added to the adverse events and Viral Infections therapeutic trials sections
  • 19 Jun 2003 A preclinical study has been added to the Viral Infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top